Neuropathies and myelopathies are disorders of the nervous system in dogs affecting both the peripheral nerves and the spinal cord. They can be caused by degenerative or inflammatory diseases, injuries or genetic predisposition. One of the most common is degenerative myelopathy in large breeds such as German Shepherds, Corgis and Boxers, leading to progressive hind limb paresis.
Conventional treatment is mainly symptomatic and includes rehabilitation, supplementation (omega-3 acids, neuroprotective vitamins), anti-inflammatory drugs and drugs that support nerve conduction. In the case of post-traumatic neuropathy or spinal cord compression, surgery may be necessary. Unfortunately, in many cases, the disease progresses despite treatment.
MSCs have neuroprotective and immunomodulatory effects. After administration, they support nerve tissue regeneration, reduce inflammation and improve nerve conduction. In dogs with degenerative myelopathy, slower disease progression and better control of motor function were observed.
👉 Check out how mesenchymal stem cells work
PRP can support the regeneration of perineural tissues and reduce microinflammation. It is used as a supportive therapy, especially for injuries and local nerve damage.
In cases of severe inflammation, IL-1 therapy helps to reduce the immune response and limit the accompanying pain or discomfort.
👉 Learn more about IL-1 pain therapy and treatment
Stage 1 – mild symptoms: rehabilitation + PRP to support repair processes.
Stage 2 – progressive symptoms: MSC to slow down progression and protect nerve tissue.
Stage 3 – advanced stage: IL-1 and palliative therapies aimed at improving the animal's quality of life.
Neuropathies and myelopathies in dogs are difficult and often progressive neurological conditions. Modern biological therapies – MSC, PRP and IL-1 – can slow down the progression of the disease, reduce inflammation and improve the patient's quality of life. Each case requires individual assessment and selection of the optimal treatment plan.
Unfortunately not – it is progressive, but biological therapies can slow down its development and improve the patient's quality of life.
MSCs do not reverse existing damage, but they can delay the progression of symptoms and support nerve regeneration.
Yes – especially in peripheral nerve regeneration and reduction of inflammation after injuries, but the restoration of nerve myelin sheaths can be achieved through the use of MSCs.
Clinical effects are usually observed after several weeks, and their duration depends on the severity of the disease.
